The administration under President Donald Trump is set to unveil significant medical findings related to autism, including potential links between Tylenol use during pregnancy and an increased risk of autism in children. The White House has reportedly advised pregnant women to avoid the medication unless necessary to treat fever, based on research from Mount Sinai and Harvard that suggests a possible association between acetaminophen and autism. The initiative, which has been a priority for Trump, follows earlier media reports indicating the administration’s examination of both Tylenol and leucovorin as possible solutions.
Concurrently, the White House is expected to promote leucovorin, a drug typically used for vitamin B9 deficiency, as a potential treatment for autism. Early trials have reportedly shown "remarkable improvements" in speech and understanding among children with autism, prompting the Food and Drug Administration’s review and renewed debate over the condition’s causes. President Trump, who has raised concerns about rising autism rates in the US, previewed the announcement during a speech on Sunday, calling it one of the biggest medical breakthroughs in the nation’s history.
The National Institutes of Health is also set to announce 13 new grants as part of its Autism Data Science Initiative, supporting studies on the causes and treatment of autism. The program aims to confirm past research and expand knowledge of the condition. Medical groups have noted that acetaminophen is generally considered safe in pregnancy but advise women to consult doctors before use. Tylenol executives recently met with administration officials to discuss the review and next steps, according to The Washington Post.
The initiative has drawn attention from various media outlets, with reports highlighting the White House’s efforts to address the autism epidemic. However, the implications of these findings remain under scrutiny, as experts caution against definitive conclusions without further study. As the administration moves forward with these announcements, the medical community and public health organizations await further details on the potential impact of these findings on public health and treatment approaches.